August 10, 2006 07:30 ET

Polydex Sponsors XVI International AIDS Conference Supporting Global Advocacy of Microbicide Development

TORONTO--(CCNMatthews - August 10, 2006) - Polydex Pharmaceuticals Limited (NASDAQ: POLXF) is pleased to announce participation in the upcoming XVI International AIDS Conference in Toronto, Canada through sponsorship of the New Prevention Technologies Zone and a special Microbicide Networking Reception. Over August 13th to the 18th 2006, more than 20,000 delegates are expected in Toronto for this, the world's largest AIDS conference. It will provide an international, open and independent forum for the exchange of ideas, knowledge and research relating to HIV/AIDS programmes, thus strengthening prevention, treatment and care efforts worldwide.

The Microbicide Networking Reception will be a rare opportunity for community members, researchers, healthcare professionals, private sector representatives, and government officials to come together and share their common interests in promoting microbicides globally.

In addition to sponsorship of the reception, Polydex will have representatives in attendance in the New Prevention Technologies Zone located in the conference's Global Village every day throughout the conference. This Zone is designed to highlight the need for a comprehensive set of prevention technologies to address the HIV pandemic, including microbicides. The Global Village will cover over 7,000 square metres (75,000 square feet) at the Metro Toronto Convention Centre in downtown Toronto. With over 20,000 delegates entering the Conference venue through the Global Village, it will have high visibility as the first point of contact, welcoming delegates and the general public every day.

Ushercell, Polydex's cellulose sulphate gel, is a leading microbicide candidate, currently undergoing large scale Phase III clinical trials at six sites in five countries to determine its effectiveness in prevention of HIV and other sexually transmitted infections. Ushercell, made from cotton, is a high molecular weight gel that acts as a viral entry inhibitor, effectively creating a dense barrier to bacteria and viruses including HIV. This barrier prevents the absorption of microbes through the vaginal canal making them unable to reach target cells; by the same mechanism, Ushercell immobilizes sperm. Recently published data indicates that Ushercell is highly effective in the prevention of pregnancy when used as directed. Ushercell is also currently being studied to determine its effectiveness at treating a common bacterial disorder among reproductive age women, Bacterial Vaginosis, a known HIV risk enhancer.

The ongoing research and development of Ushercell has been advanced in collaboration with CONRAD. CONRAD is a cooperating agency of United States Agency for International Development (USAID), committed to improving reproductive health by expanding the contraceptive choices of women and men and by helping to prevent the transmission of HIV/AIDS and other sexually transmitted diseases. CONRAD is administered through the Department of Obstetrics and Gynecology at Eastern Virginia Medical School (EVMS) in Norfolk, VA. These trials also receive significant support from Family Health International and the Bill and Melinda Gates Foundation.

In April of this year, Polydex co-sponsored the bi-annual Microbicides 2006 conference in Cape Town, South Africa. At that conference an update of clinical trial status and progress made in the microbicide development field was presented as stated in a news release dated May 15, 2006. Please visit the Company's website: www.Polydex.com for this and other news releases.

The Company's Annual Report has recently been published and is now available at the website, or by contacting Investor Relations at 1-877-945-1621.

Polydex Pharmaceuticals Limited, based in Toronto, Ontario, Canada, is engaged in the research, development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market, and also manufactures bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry.

Note: This press release may contain forward-looking statements, within the meaning of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, regarding Polydex Pharmaceuticals Limited. Actual events or results may differ materially from the Company's expectations, which are subject to a number of known and unknown risks and uncertainties including but not limited to changing market conditions, future actions by the United States Food and Drug Administration or equivalent foreign regulatory authorities as well as results of pending or future clinical trials. Other risk factors discussed in the Company's filings with the United States Securities and Exchange Commission may also affect the actual results achieved by the Company.

Contact Information

  • Investor Relations:
    North Arm Capital Services
    Linda Hughes